Page 18 - Sun Pharma

Sun Pharma plans to expand field force in India by 10% this fiscal

The Mumbai-based drug major currently employs around 11,000 Medical Representatives and related staff in India

Specialty business set to spur growth for Sun Pharma in next 3 yrs: Experts

Global specialty drug sales for Sun Pharma have grown by 39% YoY in FY22 to $674 million

From DRL to Glenmark, pharma companies see steady revenue growth in Russia

Strong sales in Q4 during war aided by 'stocking up of inventory'

Sun Pharma slips 4% on posting Rs 2,277 crores loss in Q4

The loss came on account of settlement charges of pending litigations in the US, and restructuring operations in some countries. Adjusted profit grew 18 per cent year on year (YoY) to Rs 1,582 crore.

Stocks to Watch: LIC, Delhivery, Sun Pharma, Vodafone Idea, IRCTC, SpiceJet

Stocks to Watch: Investors will react to LIC and Delhivery's Q4 numbers. The domestic GDP data for March quarter, slated to be released later today, will also be keenly monitored.

Top headlines: Voda-Idea to raise funds, Sun Pharma Q4 loss, and more

From Sun Pharma posting loss in Q4 to Vodafone-Idea engaging in talks to raise funds, here are the top headlines on Tuesday morning

Sun Pharma posts Rs 2,277 cr Q4 loss over settlement of pending US lawsuits

Provides for the settlement charges, says adjusted profit for Q4FY22 at Rs 1582 cr, up 18% YoY after excluding exceptional items of Rs 3,935.7 cr and one-time tax gain of Rs 76.4 cr

Sun Pharma eyes high single digit top line growth in FY23: Dilip Shanghvi

Drug major Sun Pharma on Monday said it expects high single-digit top-line growth in the current financial year with all its business verticals well placed to lead the charge. The company, which posted revenues of Rs 38,426 crore in FY22, aims to invest 7-8 per cent of sales in the R&D front in the ongoing fiscal. "We expect high single-digit top-line growth for FY23. All our businesses are positioned for growth. Ramp up in our global speciality business is expected to continue," Sun Pharma Managing Director Dilip Shanghvi said in an analyst call. He noted that markets across the globe were now in the process of normalising. "R&D investments are expected to be between 7-8 per cent of sales next year," Shanghvi noted. On its Halol-based manufacturing plant, he stated that the company will be filing its response to the FDA on the corrective actions to be undertaken to address the observations within the stipulated time. Earlier this month, the US health regulator had issued a ...

Top headlines: LIC Q4 PAT declines 18%; TaMo to acquire Ford's Sanand plant

Business Standard brings you the top headlines on Monday

Sun Pharma posts net loss of Rs 2,277 cr in Q4, declares Rs 3 dividend

Sun Pharma's consolidated revenue rose 10% to Rs 9,446 cr in Q4FY22

Stocks to Watch: Hindalco, Muthoot Finance, Bharti Airtel, Sun Pharma, HDFC

Stocks to Watch today: JSW Steel, FSN E-Commerce Ventures (Nykaa), Jubilant Pharma, GAIL, Glenmark Pharma, Godrej Industries, PB Fintech (Policy Bazaar) will be in focus ahead of their Q4 results.

Sun Pharma to launch new oral lipid lowering drug under Brillo brand

Claims drug has a new mechanism of action compared to currently available lipid lowering agents, is indicated for people with inherited genetic disorder

USFDA rush after 2-year lull: 20-30% new products may be open to inspection

The last two years saw limited physical inspections due to travel restrictions during the pandemic

What is USFDA's Form 483?

The US carries out regular inspections at offshore drug making units to ensure quality compliance. In a recent check, the US FDA has issued Form 483 to Sun Pharma Halol unit. Let's demystify Form 483

Sun Pharma's Halol unit gets 10 observations under USFDA's Form 483

Plant's OAI status is unchanged, hinting at status quo; Sun Pharma says will respond to observations within 15 days

Top headlines: SBI to raise up to $2 bn in FY23; Asian Paints Q4 net slips

Business Standard brings you the top headlines on Tuesday

Sun Pharma slips over 2% after USFDA issues observations for Halol facility

In the past five days, the stock has fallen over 5 per cent. In comparison, the S&P BSE Sensex declined 3.75 per cent during the same period

Aurobindo, Sun Pharma, Jubilant recall products in US market: USFDA

Leading drug firms Aurobindo Pharma, Sun Pharma and Jubilant are recalling different products in the US market for various reasons

Cipla, Ipca Lab, Zydus Life to benefit most from drug price rise: Analysts

The recent price hike, analysts said, brings some respite for the industry facing multiple headwinds such as steep raw inflation, price erosion in the US market and higher freight costs.

Sun Pharma, Ranbaxy Inc sign pact with 2 plaintiff groups to settle claims

Sun Pharma said has disputed the claims of the plaintiffs and defended these matters vigorously